Literature DB >> 35578115

B cell depletion in patients with rheumatoid arthritis is associated with reduced IL-1β in GCF.

Mükerrem Hatipoğlu1, Özlem Daltaban1, Sevcan Uğur2, Kemal Üstün3, Cahit Kaçar4, Tiraje Tuncer4, Alpdogan Kantarci5.   

Abstract

OBJECTIVES: We evaluated the effect of B cell depletion on the clinical periodontal findings and IL-1β and MMP-8 levels of the gingival crevicular (GCF) fluid in patients with rheumatoid arthritis (RA).
MATERIALS AND METHODS: Seventy patients were included in this case-control study. Twenty patients with RA were undergoing B-cell depletion treatment. The second group of RA patients (n = 20) were undergoing non-B-cell depletion treatment with Disease-Modifying Anti-Rheumatic Drugs (DMARD). Control group, with no RA, consisted of 30 individuals. Periodontal parameters including probing depth (PD), clinical attachment level (CAL), bleeding on probing (BOP), gingival index (GI), and plaque index (PI) were recorded. IL-1β and MMP-8 levels in GCF were determined using enzyme-linked immunosorbent assay. Rheumatological parameters including Disease Activity Score-28 (DAS-28), rheumatoid factor levels (RF), and anti-cyclic citrullinated peptide levels were included in the data analyses.
RESULTS: All groups were similar in PD, CAL, BOP, GI, and PI measures. GCF IL-1β levels were 1.85 ± 1.67 pg in the B-cell depletion group, 10.50 ± 13.16 pg in the DMARD group, and 34.12 ± 29.45 pg in the control group (p < 0.001). MMP-8 levels were 21.00 ± 4.23 pg in the B-cell depletion group, 8.16 ± 6.94 pg in the DMARD group, and 21.45 ± 8.67 pg in the control group (p < 0.001). DAS 28, RF, and anti-CCP were similar in RA groups.
CONCLUSIONS: GCF IL-1β levels were significantly lower in B cell depletion group, and MMP-8 levels were significantly lower in DMARD group, suggesting that rheumatoid arthritis treatments may modify biochemical parameters of GCF. CLINICAL RELEVANCE: This study suggests that host modulation therapies in RA can reduce local production of IL-1β and MMP-8. Reduction of these inflammatory cytokines and enzymes may have a beneficial effect in controlling periodontal tissue destruction.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Biological therapy; Gingival crevicular fluid; Periodontitis; Rheumatoid arthritis

Mesh:

Substances:

Year:  2022        PMID: 35578115     DOI: 10.1007/s00784-022-04378-0

Source DB:  PubMed          Journal:  Clin Oral Investig        ISSN: 1432-6981            Impact factor:   3.573


  22 in total

Review 1.  Cytokines in periodontal disease: where to from here?

Authors:  G J Seymour; E Gemmell
Journal:  Acta Odontol Scand       Date:  2001-06       Impact factor: 2.331

2.  Full-mouth profile of active MMP-8 in periodontitis patients.

Authors:  M Kraft-Neumärker; K Lorenz; R Koch; T Hoffmann; P Mäntylä; T Sorsa; L Netuschil
Journal:  J Periodontal Res       Date:  2011-09-30       Impact factor: 4.419

Review 3.  Rheumatoid arthritis and periodontal disease.

Authors:  Jean-Marie Berthelot; Benoît Le Goff
Journal:  Joint Bone Spine       Date:  2010-06-19       Impact factor: 4.929

Review 4.  B-cell inhibitors as therapy for rheumatoid arthritis: an update.

Authors:  Jennifer Kwan-Morley; Daniel Albert
Journal:  Curr Rheumatol Rep       Date:  2007-10       Impact factor: 4.592

Review 5.  B cells as under-appreciated mediators of non-auto-immune inflammatory disease.

Authors:  Barbara S Nikolajczyk
Journal:  Cytokine       Date:  2010-04-10       Impact factor: 3.861

6.  Periodontitis: Consensus report of workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions.

Authors:  Panos N Papapanou; Mariano Sanz; Nurcan Buduneli; Thomas Dietrich; Magda Feres; Daniel H Fine; Thomas F Flemmig; Raul Garcia; William V Giannobile; Filippo Graziani; Henry Greenwell; David Herrera; Richard T Kao; Moritz Kebschull; Denis F Kinane; Keith L Kirkwood; Thomas Kocher; Kenneth S Kornman; Purnima S Kumar; Bruno G Loos; Eli Machtei; Huanxin Meng; Andrea Mombelli; Ian Needleman; Steven Offenbacher; Gregory J Seymour; Ricardo Teles; Maurizio S Tonetti
Journal:  J Periodontol       Date:  2018-06       Impact factor: 6.993

7.  Association of different immunosuppressive medications with periodontal condition in patients with rheumatoid arthritis: Results from a cross-sectional study.

Authors:  Dirk Ziebolz; Annegret Rupprecht; Jan Schmickler; Laura Bothmann; Juliane Krämer; Daniel Patschan; Gerhard A Müller; Rainer F Mausberg; Jana Schmidt; Gerhard Schmalz; Susann Patschan
Journal:  J Periodontol       Date:  2018-08-23       Impact factor: 6.993

8.  Host modulation in rheumatoid arthritis patients with TNF blockers significantly decreases biochemical parameters in periodontitis.

Authors:  Kemal Üstün; Kamile Erciyas; Bünyamin Kısacık; Ufuk Sezer; Yavuz Pehlivan; Serdar Öztuzcu; Hasan Gündoğar; Ahmet Mesut Onat
Journal:  Inflammation       Date:  2013-10       Impact factor: 4.092

Review 9.  Interleukin-1β is a potential therapeutic target for periodontitis: a narrative review.

Authors:  Ran Cheng; Zhiwu Wu; Mingming Li; Meiying Shao; Tao Hu
Journal:  Int J Oral Sci       Date:  2020-01-02       Impact factor: 6.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.